These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 22674819

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T, Geng C, Yang G, Zhou H, Zhang Z, Jian Y, Chen W.
    J Clin Lab Anal; 2024 Sep; 38(17-18):e25072. PubMed ID: 39263925
    [Abstract] [Full Text] [Related]

  • 23. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
    Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer O, Engelhardt M.
    Eur J Haematol; 2009 Dec 01; 83(6):519-27. PubMed ID: 19614956
    [Abstract] [Full Text] [Related]

  • 24. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
    Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P, IFM and MAG groups.
    Leukemia; 2010 Mar 01; 24(3):623-8. PubMed ID: 20072152
    [Abstract] [Full Text] [Related]

  • 25. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C, Drach J.
    Leukemia; 2007 Jan 01; 21(1):164-8. PubMed ID: 17096015
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W, Jian Y, Du J, Li X, Zhou H, Zhang Z, Yang G, Wang G, Tian Y, Li Y, Wu Y, Fu W, Li J, Chen W.
    Cancer Med; 2020 Nov 01; 9(21):7819-7829. PubMed ID: 32881351
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.
    Haematologica; 2008 Apr 01; 93(4):560-5. PubMed ID: 18322252
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
    An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, Yi S, Xu Y, Feng X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Anderson KC, Qiu L.
    Clin Cancer Res; 2015 May 01; 21(9):2148-56. PubMed ID: 25652456
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY, Zou DH, Liu W, An G, Xu Y, Sui WW, Deng SH, Li CW, Liu H, Li J, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun 14; 39(6):496-500. PubMed ID: 30032568
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y, Ke XY, Wang J, Wang YF, Dong F, Tian L, Wan W, Jing HM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun 14; 25(3):802-806. PubMed ID: 28641639
    [Abstract] [Full Text] [Related]

  • 37. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X, Chen W, Wu Y, Li J, Chen L, Fang B, Feng Y, Liu J, Chen M, Gu J, Huang B, Li J.
    Oncologist; 2019 Nov 14; 24(11):e1132-e1140. PubMed ID: 31455749
    [Abstract] [Full Text] [Related]

  • 38. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
    Liu Z, Zeng Q, Xiang B.
    Medicine (Baltimore); 2021 May 07; 100(18):e25834. PubMed ID: 33950994
    [Abstract] [Full Text] [Related]

  • 39. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
    J Clin Oncol; 2013 Dec 01; 31(34):4325-32. PubMed ID: 24145347
    [Abstract] [Full Text] [Related]

  • 40. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.
    Am J Hematol; 2016 Nov 01; 91(11):E473-E477. PubMed ID: 27508939
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.